In the US Childhood Cancer Survivors Study cohort, second malignancy was significantly more common among GH-treated than non–GH-treated patients, and meningioma was much the most common second malignancy in the GH-treated group, accounting for 40% of all second neoplasms (5). The gene discussed is GH1; the disease is childhood malignant neoplasm.